ArticleMolecular biotechnology2026
Molecular Mechanism of Compound Glycyrrhizin in Kainic Acid-Induced Epilepsy in Rat Model.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the effects of compound glycyrrhizin (GL) on seizures in the rat model and its potential molecular mechanisms. Eighty male, healthy, and clean-graded Sprague Dawley (SD) rats, aged 1 month, were used in this study. Of these, 60 rats were selected to construct the epilepsy model and were randomly divided into the GL group (status epilepticus (SE) + GL, n = 60) and the model group (Model, n = 10), and received tail vein injections of GL or saline, respectively. Another ten normal rats served as the control group (Control). According to different doses of GL, they were divided into the high dose group (HGL, 50 mg/kg, n = 20), the medium dose group (MGL, 20 mg/kg, n = 20), and the low dose group (LGL, 10 mg/kg, n = 20). The expression levels of high mobility group box 1 (HMGB1) and Toll-like receptor-4 (TLR-4) in serum and hippocampal tissue of rats 24 h after SE were detected by enzyme-linked immunosorbent assay (ELISA) and Western blot. The neuronal density in brain tissue and the number of NeuN-positive cells in the cornu ammonis 1 (CA1) and cornu ammonis 3 (CA3) areas of rats in each group were statistically compared. SE incidence rate in the Model group was 40%, and the survival rate was 60%. The grade III seizure onset time (SOT) after kainic acid (KA) injection was (22.19 ± 2.07) min. The SOT in the SE + GL group after KA injection was (35.76 ± 3.46) min; the SE incidence rate was 10%; the survival rate was 90%. The relative expression of TLR-4 mRNA in the hippocampal tissue at different time points (3 h, 12 h, and 24 h) was markedly higher than that in the Control group, showing significance (P < 0.05). The expression levels of HMGB1 and TLR-4 in the hippocampal tissue of rats in the Model group were markedly higher than in other groups, and compared with the Model group, the expression levels of HMGB1 and TLR-4 in the hippocampal tissue of the HGL, MGL, and LGL groups were markedly reduced (P < 0.05). The neuronal density in the cerebral cortex of rats in the GL group was markedly reduced compared to the Model (P < 0.05), and the normal neuronal density in the cerebral cortex of the HGL, MGL, and LGL groups was markedly lower than that in the Control group (P < 0.05). The normal neuronal density in the cerebral cortex of the HGL and MGL groups was markedly increased compared to the Model group (P < 0.05). The number of NeuN-positive cells in the CA1 and CA3 areas of rats in the Model and SE + GL groups was greatly reduced, and the number of NeuN-positive cells in the CA1 area was markedly higher than that in the CA3 area in the HGL group and the Model group (P < 0.05). The compound GL was found to delay the onset of the first seizure in rats, reduce seizure sensitivity, and alleviate symptoms. GL treatment effectively decreased the expression of HMGB1 and TLR-4, reduced the pathological damage associated with epilepsy, and contributed to the protection of neurons.
Indexed as
Identifiers
40614045What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.